Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ02CQ
|
|||
| Drug Name |
ANAVEX 3-71
|
|||
| Synonyms |
AF-710B; Anavex 3-71; AAE07Z061B; 1235733-73-9; UNII-AAE07Z061B; 1-(2,8-Dimethyl-1-thia-3,8-diazaspiro(4.5)dec-3-yl)-3-(1H-indol-3-yl)propan-1-one; 1-Propanone, 1-(2,8-dimethyl-1-thia-3,8-diazaspiro(4.5)dec-3-yl)-3-(1H-indol-3-yl)-; SCHEMBL1326705; XWMHYQATSBWUNT-UHFFFAOYSA-N; AKOS040745497; SB17189; 1-(2,8-dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl) propan-1-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Frontotemporal dementia [ICD-11: 6D83] | Phase 1 | [1] | |
| Company |
Anavex Life Sciences
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H27N3OS
|
|||
| Canonical SMILES |
CC1N(CC2(S1)CCN(CC2)C)C(=O)CCC3=CNC4=CC=CC=C43
|
|||
| InChI |
InChI=1S/C20H27N3OS/c1-15-23(14-20(25-15)9-11-22(2)12-10-20)19(24)8-7-16-13-21-18-6-4-3-5-17(16)18/h3-6,13,15,21H,7-12,14H2,1-2H3
|
|||
| InChIKey |
XWMHYQATSBWUNT-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Muscarinic acetylcholine receptor M1 (CHRM1) | Target Info | Agonist | [2] |
| Opioid receptor sigma 1 (OPRS1) | Target Info | Agonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Cholinergic synapse | ||||
| Regulation of actin cytoskeleton | ||||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | ||||
| Reactome | Muscarinic acetylcholine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| Regulation of Actin Cytoskeleton | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04442945) A Double-blind, Randomized, Placebo-controlled, Phase 1 Safety and Tolerability, and Pharmacokinetics Study of ANAVEX3-71. U.S.National Institutes of Health. | |||
| REF 2 | AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease. Alzheimers Dement. 2018 Jun;14(6):811-823. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.